RIGL Key Statistics, Chart & Performance
The current stock price of RIGL is 36.39 USD. In the past month the price decreased by -15.36%. In the past year, price increased by 72.06%.
RIGL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to RIGL. When comparing the yearly performance of all stocks, RIGL is one of the better performing stocks in the market, outperforming 91.51% of all stocks.
RIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to RIGL. While RIGL has a great health rating, its profitability is only average at the moment.
RIGL Financial Highlights
Over the last trailing twelve months RIGL reported a non-GAAP Earnings per Share(EPS) of 6.17. The EPS increased by 4307.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 40.17% | ||
| ROA | 46.72% | ||
| ROE | 96.34% | ||
| Debt/Equity | 0.25 |
RIGL Forecast & Estimates
12 analysts have analysed RIGL and the average price target is 47.6 USD. This implies a price increase of 30.81% is expected in the next year compared to the current price of 36.39.
For the next year, analysts expect an EPS growth of 621.6% and a revenue growth 68.61% for RIGL
RIGL Ownership
RIGL Latest News, Press Relases and Analysis
About RIGL
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Company Info
RIGEL PHARMACEUTICALS INC
611 Gateway Boulevard, Suite 900
South San Francisco CALIFORNIA 94080 US
CEO: Raul R. Rodriguez
Employees: 162
Phone: 16506241100
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What does RIGEL PHARMACEUTICALS INC do?
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 162 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
What is the current price of RIGL stock?
The current stock price of RIGL is 36.39 USD. The price decreased by -2.31% in the last trading session.
What is the dividend status of RIGEL PHARMACEUTICALS INC?
RIGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RIGL stock?
RIGL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Is RIGEL PHARMACEUTICALS INC (RIGL) expected to grow?
The Revenue of RIGEL PHARMACEUTICALS INC (RIGL) is expected to grow by 68.61% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for RIGEL PHARMACEUTICALS INC?
RIGEL PHARMACEUTICALS INC (RIGL) has a market capitalization of 660.48M USD. This makes RIGL a Small Cap stock.
Can you provide the ownership details for RIGL stock?
You can find the ownership structure of RIGEL PHARMACEUTICALS INC (RIGL) on the Ownership tab.